Bowen Hanes & CO Inc Vertex Pharmaceuticals Inc Transaction History
Bowen Hanes & CO Inc
- $3.72 Billion
- Q4 2024
A detailed history of Bowen Hanes & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bowen Hanes & CO Inc holds 180,624 shares of VRTX stock, worth $88.8 Million. This represents 1.96% of its overall portfolio holdings.
Number of Shares
180,624
Previous 178,884
0.97%
Holding current value
$88.8 Million
Previous $83.2 Million
12.57%
% of portfolio
1.96%
Previous 2.19%
Shares
19 transactions
Others Institutions Holding VRTX
# of Institutions
1,757Shares Held
228MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.9 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.4 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.5 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.89 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.13 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $126B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...